<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636661</url>
  </required_header>
  <id_info>
    <org_study_id>1205M13901</org_study_id>
    <nct_id>NCT01636661</nct_id>
  </id_info>
  <brief_title>Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis</brief_title>
  <acronym>tDCS</acronym>
  <official_title>Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minnesota Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this proposal is to investigate the safety of use of transcranial
      Direct Current Stimulation (tDCS)in children with hemiparesis.

      The research question, &quot;Is transcranial Direct Current Stimulation safe for use in children
      with congenital hemiparesis?&quot; relates to two hypotheses:

        1. tDCS will not produce a major adverse event, including seizure activity.

        2. No change in paretic or nonparetic hand function or cognitive status will occur.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Completing a pilot safety study is paramount to the future goal of incorporating the tDCS
      pediatric safety data and combining tDCS and rehabilitation with constraint-induced movement
      therapy in order to improve motor outcomes beyond what rehabilitation therapies alone can
      provide and enhance quality of life for these children with hemiparesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events/Safety Assessment.</measure>
    <time_frame>Baseline, Posttest, Follow-Up Session at One-Week</time_frame>
    <description>Assessment of safety of use of tDCS in children with hemiparesis through vital signs, physician evaluation, subject report of symptoms. Reported are the number of participants who met the following criteria:
Vital Signs (either resting blood pressure or heart rate)- Any greater than 2SD of change in vital signs from pretest to posttest.
Physician Evaluation- Child identified as declining in function from pretest to posttest.
Subject Report of Symptoms- Reports of serious adverse event/symptoms from pretest to posttest.
Detailed adverse events are reported in the adverse events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hand Function Decline as Measured by Number of Participants</measure>
    <time_frame>Baseline, Posttest, Follow-Up Session at One-Week</time_frame>
    <description>Measured by the Box and Blocks Test and Grip Strength</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hemiparesis</condition>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving active tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tDCS equipment set to placebo setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>transcranial direct current stimulation- non-invasive brain stimulation</description>
    <arm_group_label>Transcranial Direct Current Stimulation</arm_group_label>
    <arm_group_label>Sham tDCS</arm_group_label>
    <other_name>transcranial direct current stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Congenital Hemiparesis confirmed by most recent MRI or CT radiologic report.

          2. Hemispheric Stroke or Periventricular Leukomalacia

          3. Ages 8-17 years old

          4. â‰¥ 10 degrees of active motion at the metacarpophalangeal joint

          5. Adequate receptive language function to follow two-step commands as evidenced by
             performance on TOKEN test of intelligence

          6. No evidence of seizure activity within the last 2 years.

          7. Subject is able to give informed assent and providing a signature, along with the
             informed consent signature of the legal guardian as evidenced by signature.

        Exclusion Criteria:

          1. Metabolic Disorders

          2. Neoplasm

          3. Epilepsy

          4. Disorders of Cellular Migration and Proliferation

          5. Acquired Traumatic Brain Injury

          6. Expressive Aphasia

          7. Pregnancy

          8. Indwelling metal or incompatible medical devices

          9. Evidence of skin disease or skin abnormalities

         10. Botulinum toxin or phenol intramuscular block within the one-month preceding tDCS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernadette Gillick, PhD, MS, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gillick BT, Feyma T, Menk J, Usset M, Vaith A, Wood TJ, Worthington R, Krach LE. Safety and feasibility of transcranial direct current stimulation in pediatric hemiparesis: randomized controlled preliminary study. Phys Ther. 2015 Mar;95(3):337-49. doi: 10.2522/ptj.20130565. Epub 2014 Nov 20.</citation>
    <PMID>25413621</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <results_first_submitted>June 22, 2015</results_first_submitted>
  <results_first_submitted_qc>June 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2015</results_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paresis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>If a child did not exhibit a motor evoked potential from the ipsilesional cortex, they were excluded from the trial after enrollment but before assignment to a group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Transcranial Direct Current Stimulation</title>
          <description>Receiving active tDCS
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
        </group>
        <group group_id="P2">
          <title>Sham tDCS</title>
          <description>tDCS equipment set to placebo setting.
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pilot study estimating a sample of children with hemiparesis. No formal sample size nor power analysis was performed.</population>
      <group_list>
        <group group_id="B1">
          <title>Transcranial Direct Current Stimulation</title>
          <description>Receiving active tDCS
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
        </group>
        <group group_id="B2">
          <title>Sham tDCS</title>
          <description>tDCS equipment set to placebo setting.
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="3.2"/>
                    <measurement group_id="B2" value="16.9" spread="2.6"/>
                    <measurement group_id="B3" value="14.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events/Safety Assessment.</title>
        <description>Assessment of safety of use of tDCS in children with hemiparesis through vital signs, physician evaluation, subject report of symptoms. Reported are the number of participants who met the following criteria:
Vital Signs (either resting blood pressure or heart rate)- Any greater than 2SD of change in vital signs from pretest to posttest.
Physician Evaluation- Child identified as declining in function from pretest to posttest.
Subject Report of Symptoms- Reports of serious adverse event/symptoms from pretest to posttest.
Detailed adverse events are reported in the adverse events module.</description>
        <time_frame>Baseline, Posttest, Follow-Up Session at One-Week</time_frame>
        <population>Pilot study therefore no sample size analysis. Completed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Direct Current Stimulation</title>
            <description>Receiving active tDCS
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Sham tDCS</title>
            <description>tDCS equipment set to placebo setting.
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events/Safety Assessment.</title>
          <description>Assessment of safety of use of tDCS in children with hemiparesis through vital signs, physician evaluation, subject report of symptoms. Reported are the number of participants who met the following criteria:
Vital Signs (either resting blood pressure or heart rate)- Any greater than 2SD of change in vital signs from pretest to posttest.
Physician Evaluation- Child identified as declining in function from pretest to posttest.
Subject Report of Symptoms- Reports of serious adverse event/symptoms from pretest to posttest.
Detailed adverse events are reported in the adverse events module.</description>
          <population>Pilot study therefore no sample size analysis. Completed per protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Change in Vital Signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decline in Physician Evaluation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hand Function Decline as Measured by Number of Participants</title>
        <description>Measured by the Box and Blocks Test and Grip Strength</description>
        <time_frame>Baseline, Posttest, Follow-Up Session at One-Week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Direct Current Stimulation</title>
            <description>Receiving active tDCS
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
          </group>
          <group group_id="O2">
            <title>Sham tDCS</title>
            <description>tDCS equipment set to placebo setting.
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Hand Function Decline as Measured by Number of Participants</title>
          <description>Measured by the Box and Blocks Test and Grip Strength</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transcranial Direct Current Stimulation</title>
          <description>Receiving active tDCS
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
        </group>
        <group group_id="E2">
          <title>Sham tDCS</title>
          <description>tDCS equipment set to placebo setting.
tDCS: transcranial direct current stimulation- non-invasive brain stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <description>Reports of tingling under the electrodes. Assessed verbally by participant feedback at scheduled intervals: pre/post and follow-up sessions.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Burning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bernadette Gillick</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612.626.6415</phone>
      <email>brown029@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

